Literature DB >> 1901105

Triacetin: a potential parenteral nutrient.

J W Bailey1, M W Haymond, J M Miles.   

Abstract

UNLABELLED: Triacetin, the water-soluble triglyceride of acetate, was infused in mongrel dogs at isocaloric (N = 6) or hypercaloric (approximately 1.5 REE, N = 7) rates in mongrel dogs for 3 hr. Ketone body and glucose production rates were quantified with [13C2] acetoacetate and [3H]glucose, respectively. Four additional animals were infused with glycerol to serve as controls for the hypercaloric triacetin infusion. Energy expenditure was determined in the isocaloric experiments.
RESULTS: no evidence of acute toxicity was observed during triacetin infusion at either rate. Plasma acetate concentrations increased from basal levels to approximately 1 and approximately 13 mmol/liter in the isocaloric and hypercaloric experiments, respectively. Plasma lactate and pyruvate concentrations decreased dramatically after 30 min of both isocaloric and hypercaloric triacetin infusions. Glucose production rates did not increase in either group, but glucose clearance decreased significantly in both groups (p less than 0.05) over the last hour of triacetin infusion. Plasma ketone body concentrations increased from 1.4 to 3.5 and 1.8 to 13.5 mumol/kg.min, respectively, during isocaloric and hypercaloric triacetin infusion. Resting energy expenditure increased from 3.0 +/- 0.3 to 4.0 +/- 0.5 kcal/kg.hr during isocaloric triacetin infusion (p less than 0.05). These studies indicate that triacetin can be administered to dogs at high rates without overt toxicity. The decrease in glucose clearance may represent competition between carbohydrate (glucose) and lipid (acetate). Triacetin infusion resulted in significant increases in ketone body production and concentration. These preliminary data indicate that triacetin may have a future role as a parenteral nutrient, and that further studies of its use are warranted.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901105     DOI: 10.1177/014860719101500132

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  6 in total

1.  Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.

Authors:  Andrew R Tsen; Patrick M Long; Heather E Driscoll; Matthew T Davies; Benjamin A Teasdale; Paul L Penar; William W Pendlebury; Jeffrey L Spees; Sean E Lawler; Mariano S Viapiano; Diane M Jaworski
Journal:  Int J Cancer       Date:  2013-09-30       Impact factor: 7.396

2.  Improvement in mechanical properties and biodegradability of PLA using poly(ethylene glycol) and triacetin for antibacterial wound dressing applications.

Authors:  Bita Darabian; Hamed Bagheri; Soheila Mohammadi
Journal:  Prog Biomater       Date:  2020-05-30

3.  Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease.

Authors:  Peethambaran Arun; Chikkathur N Madhavarao; John R Moffett; Kristen Hamilton; Neil E Grunberg; Prasanth S Ariyannur; William A Gahl; Yair Anikster; Steven Mog; William C Hallows; John M Denu; Aryan M A Namboodiri
Journal:  J Inherit Metab Dis       Date:  2010-05-13       Impact factor: 4.982

4.  Intra-gastric triacetin alters upper gastrointestinal motility in conscious dogs.

Authors:  Kazumasa Oosaka; Masaaki Tokuda; Naohiro Furukawa
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

5.  Metabolic acetate therapy for the treatment of traumatic brain injury.

Authors:  Peethambaran Arun; Prasanth S Ariyannur; John R Moffett; Guoqiang Xing; Kristen Hamilton; Neil E Grunberg; John A Ives; Aryan M A Namboodiri
Journal:  J Neurotrauma       Date:  2010-01       Impact factor: 5.269

6.  Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability.

Authors:  Tarek A Ahmed; Hany M Ibrahim; Ahmed M Samy; Alaa Kaseem; Mohammad T H Nutan; Muhammad Delwar Hussain
Journal:  AAPS PharmSciTech       Date:  2014-03-20       Impact factor: 3.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.